SynthesisBlood advances2020

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.

Claudia Vener et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.